ライフサイエンスコーパス: alanine aminotransferase

1 on markers such as increased level of serum alanine aminotransferase.

2 els of lactate dehydrogenase, aspartate, and alanine aminotransferase.

3 tory cytokine concentration, cystatin C, and alanine aminotransferase.

4 22% had advanced fibrosis and 54% had normal alanine aminotransferase.

5 blood-fed Aedes aegypti mosquitoes requires alanine aminotransferase.

6 routinely assayed in clinical laboratories (alanine aminotransferase 1, C-reactive protein, and myog

7 ]), vomiting (125 [66%]), and an increase in alanine aminotransferase (114 [60%]) in the ceritinib gr

8 ), colitis (19 [5%] vs nine [2%]), increased alanine aminotransferase (12 [3%] vs two [1%]), and hypo

9 verse events were increases in lipase (15%), alanine aminotransferase (12%), and aspartate aminotrans

10 atched cold-stored DCD livers regarding peak alanine-aminotransferase (1239 vs 2065 U/L, P = 0.02), i

11 roup versus the placebo group were increased alanine aminotransferase (146 [25%] of 573 patients vs s

12 (affecting >/=2% of patients) were increased alanine aminotransferase (17 [3%] of 573 vs one [<1%] of

13 dermatitis acneiform (20 [9%]) and increased alanine aminotransferase (17 [8%]).

14 erse events were transaminase increases (40% alanine aminotransferase, 17% aspartate aminotransferase

15 ransferase, 22.67 U/L (19.94-25.41 U/L); for alanine aminotransferase, 21.77 U/L (18.96-24.59 U/L); f

16 on to continue the trial (relative change in alanine aminotransferase -24%, 95% CI -45 to -3).

17 g dose escalation included grade 3 increased alanine aminotransferase (240 mg daily) and grade 4 dysp

18 +/- 2.1 vs 36.0 +/- 9.3 mg/dL; p </= 0.001), alanine aminotransferase (266.5 +/- 295.2 vs 861.8 +/- 8

19 , increased amylase (31 [6%]), and increased alanine aminotransferase (28 [5%]), whereas in the sunit

20 40 patients in the placebo group), increased alanine aminotransferase (32 [6%] vs four [<1%]), and hy

21 nsferase (32.4 +/- 17.4 vs 21.5 +/- 6.9U/L), alanine aminotransferase (39.9 +/- 28.6U/L vs 23.8 +/- 1

22 participants developed a transaminase rise (alanine aminotransferase 4.5-5.9 times the upper limit o

23 criteria, those with CFLD had higher median alanine aminotransferase (42 versus 27, P = 0.005), aspa

24 ubjects with a FibroScan >6.8 kPa had higher alanine aminotransferase (42 versus 28U/L, P = 0.02), AS

25 e aminotransferase (65 [26%]), and increased alanine aminotransferase (47 [19%]).

26 uparlisib versus placebo group were elevated alanine aminotransferase (63 [22%] of 288 patients vs fo

27 mmon adverse events were increased levels of alanine aminotransferase (64%) and aspartate aminotransf

28 Elevations in alanine aminotransferase (7 [11.3%] SAD), aspartate amin

29 rica were more likely to have elevated serum alanine aminotransferase (72% vs. 50%; P < 0.01) and hig

30 3-4 laboratory abnormalities were increased alanine aminotransferase (73 [30%] patients) and increas

31 -type mice accompanied by elevated levels of alanine aminotransferase, a marker of liver injury.

32 e associated with a significant reduction in alanine aminotransferase activity [ALT, weighted mean di

33 histological staining, measurement of serum alanine aminotransferase activity, and expression analys

34 HFD also increased hepatic steatosis, plasma alanine aminotransferase activity, inflammation, oxidati

35 on liver mass, serum cholesterol, and serum alanine aminotransferase activity.

36 y mass and liver damage as measured by serum alanine aminotransferase activity.

37 e centrilobular necrosis and increased serum alanine aminotransferase activity.

38 ) T cells and a transient elevation in serum alanine aminotransferase activity.

39 y histology, propidium iodide injection, and alanine aminotransferase after IRI.

40 HBV DNA target not detected, normal level of alanine aminotransferase) after removal of all therapy.

41 lation, including nitrate reductase (NR) and alanine aminotransferase (AlaAT), were induced during se

42 excess nitrogen, we investigated the role of alanine aminotransferase (ALAT) in blood-fed Aedes aegyp

43 lysis; aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT); oxidative stress (malon

44 ALF-CLD, the median age at onset was higher, alanine aminotransferase, albumin, and International Nor

45 In the SOS cohort, E167K carriers had higher alanine aminotransferase ALT and lower lipid levels (P <

46 cluded HBV DNA >=2000 IU/mL, with or without alanine aminotransferase (ALT) >=2-fold the upper limit

47 positive women and HBeAg-negative women with alanine aminotransferase (ALT) >=40 IU/L as a predictor

48 sitive adults with HBV DNA > 10(7) IU/mL and alanine aminotransferase (ALT) <= 1.5 times the upper li

49 amma-glutamyl transferase (-30%; P < 0.001), alanine aminotransferase (ALT) (-49%; P = 0.009), and as

50 pectively), corrected T1 (cT1; -8% and -9%), alanine aminotransferase (ALT) (-67% and -60%), aspartat

51 r inhibitor-1 (markers for fibrinolysis) and alanine aminotransferase (ALT) (marker of ischemia-reper

52 retinol-binding protein by using ELISA, and alanine aminotransferase (ALT) activity by using a color

53 s the induction of immune tolerance, and the alanine aminotransferase (ALT) activity in these mice re

54 ad increased contents, which may result from alanine aminotransferase (ALT) and branched-chain amino

55 brosis significantly reduced serum levels of alanine aminotransferase (ALT) and liver steatosis and f

56 rtate aminotransferase (AST) was higher than alanine aminotransferase (ALT) at admission (46 vs. 30 U

57 increased BM sproc recruitment, and reduced alanine aminotransferase (ALT) by 92% and 77% at 5 weeks

58 ges in qualitative serum HBsAg, HBV DNA, and alanine aminotransferase (ALT) concentrations in additio

59 ety outcomes were serious adverse events and alanine aminotransferase (ALT) concentrations over 12 we

60 Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) decreased significantly i

61 Analysis of peak values of alanine aminotransferase (ALT) during COVID-19 showed mo

62 Clinical implications of persistent alanine aminotransferase (ALT) elevation and associated

63 grade 4 aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation with fevers, an

64 Interpretations of elevated blood levels of alanine aminotransferase (ALT) for drug-induced liver in

65 otential mediating role of viral load and/or alanine aminotransferase (ALT) in the relation of smokin

66 th the occurrence of at least 1 flare in the alanine aminotransferase (ALT) level (>200 U/L; P = .007

67 lence of and risk factors for elevated serum alanine aminotransferase (ALT) level among adult childho

68 RS was associated with an increase in plasma alanine aminotransferase (ALT) level of 26% in those wit

69 defined as viral DNA levels >2000 IU/mL and alanine aminotransferase (ALT) levels >80 U/mL, respecti

70 of pruritus, disappearance of jaundice, and alanine aminotransferase (ALT) levels <1.5 times the upp

71 The TDF group had less incidence of maternal alanine aminotransferase (ALT) levels above two times th

72 liver fibrosis, inflammation, steatosis, and alanine aminotransferase (ALT) levels and viscoelastic a

73 ular injury is identified internationally by alanine aminotransferase (ALT) levels equal to or exceed

74 aminotransferase (AST) and 35% had elevated alanine aminotransferase (ALT) levels on admission.

75 erum insulin, fasting serum lipids and serum alanine aminotransferase (ALT) levels were measured and

76 Observational studies of the association of alanine aminotransferase (ALT) levels with ischaemic hea

77 Correlates of FLD and its relationship with alanine aminotransferase (ALT) overtime were examined in

78 Alanine aminotransferase (ALT) predicts type 2 diabetes

79 index (APRI), fibrosis-4 index (FIB-4), AST/alanine aminotransferase (ALT) ratio (AAR), and age-plat

80 ted positive and had higher initial and peak alanine aminotransferase (ALT) than those who tested neg

81 The primary endpoint was the time for serum alanine aminotransferase (ALT) to fall below 100 U/L.

82 were metabolically abnormal or had elevated alanine aminotransferase (ALT) were higher than among th

83 CatD and alanine aminotransferase (ALT) were measured in plasma.

84 43.9% had HBV DNA>/=20,000 IU/mL, and 26.7% alanine aminotransferase (ALT)>/=2x upper limit of norma

85 mical assay capable of quantifying levels of alanine aminotransferase (ALT), a primary biomarker asso

86 aspartate aminotransferase, alanine aminotransferase (ALT), acute kidney injury (AKI

87 ate the causal effects of the liver enzymes, alanine aminotransferase (ALT), alkaline phosphatase (AL

88 YCHT treatment substantially reduced serum alanine aminotransferase (ALT), alkaline phosphatase (AS

89 including gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), and aspartate aminotrans

90 L), high-density lipoprotein, triglycerides, alanine aminotransferase (ALT), and aspartate aminotrans

91 levated gamma-glutamyl transferase (GGT) and alanine aminotransferase (ALT), and higher number of hea

92 ic acids and flavones reduced blood glucose, alanine aminotransferase (ALT), aspartate aminotransfera

93 pathological changes and increases in serum alanine aminotransferase (ALT), aspartate aminotransfera

94 ere constructed using baseline and change in alanine aminotransferase (ALT), aspartate aminotransfera

95 Alanine aminotransferase (ALT), aspartate aminotransfera

96 Alanine aminotransferase (ALT), aspartate aminotransfera

97 Serum levels of alanine aminotransferase (ALT), aspartate aminotransfera

98 of salivary concentrations of total protein, alanine aminotransferase (ALT), aspartate aminotransfera

99 Finally, blood levels of alanine aminotransferase (ALT), aspartate aminotransfera

100 Alanine aminotransferase (ALT), gamma-glutamyltransferas

101 three groups: patients with steatosis/normal alanine aminotransferase (ALT), steatosis/elevated ALT,

102 with normal or minimally elevated levels of alanine aminotransferase (ALT).

103 P( KO) mice fed an HFD exhibited lower serum alanine aminotransferase (ALT)/aspartate aminotransferas

104 damage, high aspartate (AST, >49.9 IU/L) and alanine aminotransferase (ALT, >56.1 IU/L), to the relat

105 idence interval [CI]: 1.72-3.36; P < 0.001), alanine aminotransferase (ALT; OR, 1.24; 95% CI: 1.12-1.

106 cid (BA) (>6 mumol/l) and elevation of serum alanine aminotransferases (ALT) (>45 U/l).

107 Also, we assessed serum levels of alanine-aminotransferase (ALT), liver histology, hepatic

108 steine treatment beyond the standard course (alanine aminotransferase [ALT] activity >100 U/L).

109 ects were classified as presumed NAFLD (pNF; alanine aminotransferase [ALT] level >/= 20 for women or

110 In a mouse model of ALD, liver injury (alanine aminotransferase [ALT]) and steatosis were preve

111 erases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) are usually increased in

112 erases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]), alkaline phosphastase,

113 alculated as (age x AST)/(platelet x radical alanine aminotransferase [ALT]).

114 ver tests (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [AL

115 pase (three [1%] of 268 patients), increased alanine aminotransferase, anaemia, and fatigue (two [1%]

116 Chronic Hepatitis Cohort Study, 78% had >/=1 alanine aminotransferase and 37% had >/=1 hepatitis B vi

117 s B surface antigen, and 97% of patients had alanine aminotransferase and 44% had hepatitis B virus D

118 seen by decreases of 53% (p < 0.05) in serum alanine aminotransferase and 74% (p < 0.05) in hepatic t

119 and regression tree models based on level of alanine aminotransferase and abundance of genes encoding

120 of balloon degeneration, and elevated serum alanine aminotransferase and aspartate aminotransferase

121 ncreases in liver and serum BA levels, serum alanine aminotransferase and aspartate aminotransferase

122 ferences in histologic response rates, serum alanine aminotransferase and aspartate aminotransferase

123 ation was accompanied by decreased levels of alanine aminotransferase and aspartate aminotransferase

124 ge in vivo and correspondingly reduced serum alanine aminotransferase and aspartate aminotransferase

125 with 200 mg twice a day (grade 3 increase of alanine aminotransferase and aspartate aminotransferase)

126 concentrations in liver; and serum levels of alanine aminotransferase and aspartate aminotransferase.

127 rum of Sirt1LKO mice had increased levels of alanine aminotransferase and aspartate aminotransferase.

128 demonstrated 40% and 45% decrease in plasma alanine aminotransferase and BA levels, respectively.

129 verity of NAFLD was associated with level of alanine aminotransferase and cardiometabolic risk factor

130 However, HFD elevated plasma alanine aminotransferase and creatinine, caused iWAT hyp

131 ng body weight, blood cell counts, and serum alanine aminotransferase and creatinine.

132 ndex > 40), in combination with elevation of alanine aminotransferase and gamma-glutamyl transferase,

133 as indicated by lower levels of TCDD-induced alanine aminotransferase and hepatic triglycerides.

134 played much less damage as assessed by serum alanine aminotransferase and histology.

135 , the most common of which were increases in alanine aminotransferase and in aspartate aminotransfera

136 ling (TUNEL) staining, circulating levels of alanine aminotransferase and lactate dehydrogenase, and

137 onditioning each significantly reduced serum alanine aminotransferase and liver mRNA expression of tu

138 attenuated APAP-induced serum elevations of alanine aminotransferase and microRNA-122 and completely

139 No patients had elevations in alanine aminotransferase and no patients prematurely dis

140 e 3 increased aspartate aminotransferase and alanine aminotransferase and one grade 4 increased lipas

141 trong positive associations between elevated alanine aminotransferase and pretreatment IP-10 and betw

142 tion and regression tree model with level of alanine aminotransferase and relative abundance of the l

143 Median alanine aminotransferase and serum HBV DNA levels were 2

144 Serum levels of alanine aminotransferase and tumor necrosis factor-alpha

145 ine phosphatase, aspartate aminotransferase, alanine aminotransferase) and areas of liver parenchymal

146 atio, bilirubin, aspartate aminotransferase, alanine aminotransferase) and liver histology (hematoxyl

147 n level, sedimentation rate, and creatinine, alanine aminotransferase, and aspartate aminotransferase

148 duced hepatic neutrophil accumulation, serum alanine aminotransferase, and attenuated liver injury af

149 , when compared to levels of HBV DNA, HBsAg, alanine aminotransferase, and HBV genotype, age, and sex

150 creased necrosis, infiltrating CD8(+) cells, alanine aminotransferase, and proinflammatory cytokines.

151 anaemia, dyspnoea, hyponatraemia, increased alanine aminotransferase, and thrombocytopenia (three [1

152 patocellular injury glutamate dehydrogenase, alanine aminotransferase, aspartate aminotransferase (AS

153 tation significantly reduced plasma glucose, alanine aminotransferase, aspartate aminotransferase, AG

154 virus-infected patients was the elevation in alanine aminotransferase, aspartate aminotransferase, al

155 ymes than control group (mean difference for alanine aminotransferase, aspartate aminotransferase, al

156 We assessed concentrations of alanine aminotransferase, aspartate aminotransferase, an

157 (P < 0.01) serum total lipids, cholesterol, alanine aminotransferase, aspartate aminotransferase, an

158 ction in ALP had greater reductions in serum alanine aminotransferase, aspartate aminotransferase, ga

159 age older than 50 years; increased levels of alanine aminotransferase, aspartate aminotransferase, or

160 ly along with significant elevation of serum alanine aminotransferase, aspartate aminotransferase, to

161 included neutropenia (14.5%) and reversible alanine aminotransferase/aspartate aminotransferase elev

162 iated with lower serum alkaline phosphatase; alanine aminotransferase; aspartate aminotransferase; ga

163 ose with elevated aspartate aminotransferase/alanine aminotransferase (AST/ALT).

164 A planned interim analysis of change in alanine aminotransferase at 24 weeks undertaken before e

165 ly to be IL28B non-CC, and had a lower serum alanine aminotransferase at baseline than non-black pati

166 % CI 0.005-0.49; P = 0.01), normal levels of alanine aminotransferase at the end of intervention (OR

167 ansferase (beta = 2.60; 95% CI: 0.99, 4.20), alanine aminotransferase (beta = 3.70; 95% CI: 1.78, 5.6

168 ripts, including XDH1, glutamine synthetase, alanine aminotransferase, catalase, superoxide dismutase

169 steatosis, inflammation, and serum levels of alanine aminotransferase compared with mice given a cont

170 s of ALP, gamma-glutamyl transpeptidase, and alanine aminotransferase, compared with placebo, in pati

171 %), elevated lipase level (15; 5%), elevated alanine aminotransferase concentration (12; 4%), and abd

172 s), increased aspartate aminotransferase and alanine aminotransferase concentration (14 [38%] patient

173 events in the ceritinib group were increased alanine aminotransferase concentration (24 [21%] of 115

174 One patient was ineligible (alanine aminotransferase concentration was above the req

175 fractures (36 [9%] vs 12 [3%]) and increased alanine aminotransferase concentrations (34 [9%] vs 28 [

176 verse events were rash (89 [56%]), increased alanine aminotransferase concentrations (74 [46%]), and

177 atients), nausea (three [9%]), and increased alanine aminotransferase concentrations (three [9%]).

178 ropenia (15 [50%] of 30 patients), increased alanine aminotransferase concentrations (two [7%] patien

179 Increased alanine aminotransferase concentrations caused two (3%)

180 r 2 x 10(3) IU/mL (HBeAg-negative) and serum alanine aminotransferase concentrations less than seven

181 DNA concentrations of >20 000 IU/mL), serum alanine aminotransferase concentrations of greater than

182 Elevations of aspartate and alanine aminotransferase concentrations of three or more

183 ons in plasma aspartate aminotransferase and alanine aminotransferase concentrations; hepatic steatos

184 crease in the group given placebo; levels of alanine aminotransferase decreased 21%-35% on average am

185 ctinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), a

186 e observed, including 1 case of asymptomatic alanine aminotransferase elevation.

187 V reactivation in this cohort exhibited peak alanine aminotransferase elevations >2 times the upper l

188 Limited, asymptomatic, and transient alanine aminotransferase elevations in the low-dose (n =

189 Treatment-emergent grade 3 or 4 alanine aminotransferase elevations were observed in 4 p

190 eatment discontinuation, including 2 grade 4 alanine aminotransferase elevations.

191 FLD was associated with increasing levels of alanine aminotransferase, fasting glucose level, hyperte

192 ]), thrombocytopenia (five [28%]), increased alanine aminotransferase (five [28%]), and hypokalaemia

193 eatine phosphokinase (seven [8%]), increased alanine aminotransferase (five [6%]), and increased aspa

194 should be followed up on a monthly basis for alanine aminotransferase followed by quantitative HBV DN

195 rom 49.3 +/- 8.2 to 37.4 +/- 7) and level of alanine aminotransferase (from 52.1 +/- 25.7 IU/L to 25.

196 onths (symptomatic seroconversion illness or alanine aminotransferase > 10 x upper limit of normal) o

197 dverse events (aspartate aminotransferase or alanine aminotransferase > 400; acetaminophen 9.5% vs pl

198 diate viral load [IVL]) and normal levels of alanine aminotransferase, HBcrAg levels of 10 KU/mL or m

199 ver follow-up time, with increasing level of alanine aminotransferase, hemoglobin A1C (P<.05), gamma-

200 cell count (HR 2.45, p 0.011), raised serum alanine aminotransferase (HR 4.22, p 0.016), raised seru

201 e in 82%, aspartate aminotransferase in 70%, alanine aminotransferase in 54%, and creatinine kinase i

202 We also measured levels of TNF and alanine aminotransferase in serum from mice.

203 Patients with elevated alanine aminotransferase in specialty care were more lik

204 elevation in four (15%) patients, increased alanine aminotransferase in two (8%) patients, increased

205 ts indicated a causal role of increased ALT (alanine aminotransferase) in the development of type 2 d

206 inotransferase increase (39%), nausea (38%), alanine aminotransferase increase (28%), and dysgeusia (

207 0%] of 425 patients in the sunitinib group), alanine aminotransferase increase (54 [13%] vs 11 [3%]),

208 occurring in more than two patients included alanine aminotransferase increase (five [14%]), pyrexia

209 4 adverse events were pyrexia (four [11%]), alanine aminotransferase increase (four [11%]), hyperten

210 uzumab), fatigue (three [1%] vs seven [3%]), alanine aminotransferase increase (three [1%] vs four [2

211 y quantitative HBV DNA testing in those with alanine aminotransferase increase.

212 (39.1% vs 28.1%), pyrexia (38.7% vs 26.0%), alanine aminotransferase increased (33.9% vs 22.8%), and

213 loped fully reversible, asymptomatic grade 3 alanine aminotransferase increases (one on 50 mg, two on

214 an injury as determined by serum creatinine, alanine aminotransferase, lactate dehydrogenase, and cre

215 values of aspartate aminotransferase (AST), alanine aminotransferase, lactate dehydrogenase, and cre

216 parameters (PP) (aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, glucose

217 f active disease (hepatic steatosis >10% and alanine aminotransferase level >=45 U/L) randomized 1:1

218 rtension (in 21% of the patients), increased alanine aminotransferase level (in 11%), increased aspar

219 Elevations in the alanine aminotransferase level (to >3 times the upper li

220 histology, diabetes, sex, age, and change in alanine aminotransferase level and change in FIB-4 index

221 e 12 secondary outcomes, including change in alanine aminotransferase level and diet adherence.

222 d 5 were statistically significant including alanine aminotransferase level and diet adherence.

223 ansferase level <= 49 U/L, and a decrease in alanine aminotransferase level at week 24 by 17 U/L or m

224 1 incident each of grade 4 adverse events of alanine aminotransferase level elevation and rectal hemo

225 The geometric mean decrease in alanine aminotransferase level from baseline to 8 weeks

226 Liver enzyme levels were elevated, with an alanine aminotransferase level of 48 U/L (0.80 ukat/L) (

227 Liver enzyme levels were elevated, with an alanine aminotransferase level of 48 U/L (0.80 ukat/L) (

228 adverse event was an elevation in the serum alanine aminotransferase level to 1.5 times the upper li

229 At 20 weeks, the alanine aminotransferase level was normal in 11 of 36 pa

230 NAS, triglyceride levels, and a decrease in alanine aminotransferase level) to significantly associa

231 e primary end point was normalization of the alanine aminotransferase level.

232 e start of the immune-clearance phase (serum alanine aminotransferase levels > 30 IU/l) before the ag

233 ith hepatitis C virus, persons with elevated alanine aminotransferase levels (>/=19 IU/L for women an

234 5 birth cohort (4.4 [3.8-5.1]), and elevated alanine aminotransferase levels (4.8 [4.2-5.6]) as indep

235 diarrhoea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).

236 on accompanied by a significant reduction of alanine aminotransferase levels and of proinflammatory c

237 Increasing age (>40 years), male sex, alanine aminotransferase levels and visceral adipose tis

238 Abnormal alanine aminotransferase levels at admission can indicat

239 The alanine aminotransferase levels decreased from 79.9 +/-

240 African Americans (all P < 0.05), with high alanine aminotransferase levels in Hispanics (P < 0.05)

241 Alanine aminotransferase levels increased in ALGS after

242 Four of the 6 patients (67%) had increased alanine aminotransferase levels of more than 1.5 times t

243 de association study combining cirrhosis and alanine aminotransferase levels performed in 5 discovery

244 while 4 of 22 patients (18%) with increased alanine aminotransferase levels showed positive reactivi

245 y higher mean aspartate aminotransferase and alanine aminotransferase levels throughout pregnancy, bu

246 Patients were ineligible if alanine aminotransferase levels were higher than ten tim

247 72,705 controls and 362,539 individuals with alanine aminotransferase levels).

248 rm, difference = 20.2%, 95% CI: 10.7, 30.5), alanine aminotransferase levels, and aspartate transamin

249 Notably, increases in alanine aminotransferase levels, apoptotic markers, and

250 Liver inflammation, alanine aminotransferase levels, chemokine (C-X-C) ligan

251 Five (42%) patients had raised alanine aminotransferase levels, four (33%) had raised a

252 nt liver injury dramatically decreased serum alanine aminotransferase levels, histological injury, th

253 ge was assessed by hematoxylin and eosin and alanine aminotransferase levels.

254 nt amelioration of ferritin, fibrinogen, and alanine aminotransferase levels.

255 s mirrored by significantly increased plasma alanine aminotransferase levels.

256 ure cytokines and a marker of liver failure (alanine aminotransferase); liver tissues were collected

257 et NAFLD nor in 100 healthy individuals with alanine aminotransferase <22/20 IU/mL.

258 X-82 including leg cramps (n = 2), elevated alanine aminotransferase (n = 2), diarrhea (n = 1), and

259 de levels and improved liver markers such as alanine aminotransferase, NAFLD activity score, and fibr

260 tiviral therapy compared to placebo improved alanine aminotransferase normalization (risk ratio [RR]

261 g seroconversion (RR = 2.1, 95% CI 1.3-3.5), alanine aminotransferase normalization (RR = 1.4, 95% CI

262 improve HBV DNA suppression and frequency of alanine aminotransferase normalization and HBeAg serocon

263 cantly declined upon viremia suppression and alanine aminotransferase normalization induced by NUC th

264 odel including weight loss, type 2 diabetes, alanine aminotransferase normalization, age, and a nonal

265 ty endpoint was incidence of hepatotoxicity: alanine aminotransferase of greater than five times the

266 lobin (45 [22%] patients), and elevations in alanine aminotransferase or aspartate aminotransferase (

267 pper limit of normal (ULN) or Hy's criteria (alanine aminotransferase or aspartate aminotransferase g

268 e, HBV DNA below 2000 IU/mL, normal level of alanine aminotransferase) or functional cure (HBsAg belo

269 ed by increased leukocyte count (P < .0001), alanine aminotransferase (P = .024), and aspartate trans

270 creased levels of blood lactate (P = 0.007), alanine aminotransferase (P = 0.027), bilirubin (P = 0.0

271 016) and higher celiac antibody (p < 0.001), alanine aminotransferase (p = 0.035) and thyroid-stimula

272 te aminotransferase (P = 5.20 x 10(-13)) and alanine aminotransferase (P = 4.98 x 10(-8)).

273 on of phenylhydrazine, resulted in increased alanine aminotransferase plasma levels and NGAL expressi

274 POD3 of 7 total bilirubin and alanine aminotransferase; POD3 aspartate aminotransferas

275 A risk score according to age, sex, alanine aminotransferase, previous chronic liver disease

276 reased aspartate aminotransferase, increased alanine aminotransferase, rash, and dyspnoea being the m

277 showing increased aspartate aminotransferase-alanine aminotransferase ratios, but, to date, has not b

278 d secondary outcomes: reduced mean levels of alanine aminotransferase (reduction, 53 +/- 88 U/L vs 8

279 itis B surface antigen (HBsAg), HBV DNA, and alanine aminotransferase results obtained while on DAA t

280 Alanine aminotransferase reversibly increased to more th

281 ood count, serum chemistry profile, level of alanine aminotransferase, rheumatoid factor activity, C4

282 [ROC AUC]) 0.83 [95% CI 0.74-0.92]), but not alanine aminotransferase (ROC AUC 0.46 [0.35-0.57]).

283 ty in other populations were associated with alanine aminotransferase (rs200088103; p.Arg133Trp, P =

284 erbilirubinemia (seven of 44, 16%), elevated alanine aminotransferase (seven of 44, 16%), and pain (s

285 xcept lactate correlated with EAD, 90-minute alanine aminotransferase showing the highest area under

286 enia (six [5%] vs three [4%]), and increased alanine aminotransferase (six [5%] vs two [3%]).

287 itis (12 [13%] of 94 patients) and increased alanine aminotransferase (ten [11%]) in the combination

288 H correlated more closely with gold standard alanine aminotransferase than miR-122, and there was a s

289 an isolated grade 4 increase in the level of alanine aminotransferase that led to treatment discontin

290 rash (11 [8%] of 141 patients) and increased alanine aminotransferase (three [2%]).

291 seline and hepatitis flare as an increase in alanine aminotransferase to >/=3 times the upper limit o

292 Mean aspartate aminotransferase, alanine aminotransferase, total bilirubin, and gamma glu

293 tions in serum by >98%, and decreased plasma alanine aminotransferase, total bilirubin, and serum alk

294 and no relevant laboratory abnormalities in alanine aminotransferase, total bilirubin, or hemoglobin

295 elated serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), in

296 For all subjects combined, alanine aminotransferase was reduced by 15.8 +/- 8.4% (P

297 on, and hyperkalaemia, and grade 4 increased alanine aminotransferase were reported in one patient ea

298 that facilitates the breakdown of alanine by alanine aminotransferase when reoxygenation occurs.

299 lirubin, international normalized ratio, and alanine aminotransferase within 3 days posttransplant.

300 MC-2 in HS also decreased levels of alanine aminotransferase, zonula occludens-1, and interl